CytoSorbents Corporation — FY 2017 Form 10-K
Reporting period: Fiscal year ended December 31, 2017. The filing also reports unaudited fourth-quarter results. CytoSorbents develops and commercializes blood-purification devices; its flagship CytoSorb product is CE-marked in the EU and sold internationally, but was not approved for human use in the United States at year-end.
Financial performance and position
| Metric | FY 2017 | FY 2016 | Change |
|---|---|---|---|
| Total revenue | $15.15 million | $9.53 million | Up 59% |
| Product sales | $13.38 million | $8.21 million | Up 63% |
| Grant income | $1.77 million | $1.32 million | Up 34% |
| Gross profit | $9.63 million | $5.57 million | Up 73% |
| Product gross margin | Approximately 71% | Approximately 67% | Improved |
| Operating expenses | $19.47 million | $17.07 million | Up 14% |
| Operating loss | $(9.84) million | $(11.49) million | Narrowed |
| Net loss | $(8.46) million | $(11.76) million | Narrowed |
| Basic and diluted loss per share | $(0.32) | $(0.46) | Improved |
Fourth quarter: Revenue was $4.65 million, gross profit was $3.38 million, operating loss was $3.81 million, and net loss attributable to common stockholders was $3.15 million, or $0.12 per share. In Q4 2016, revenue was $3.08 million, operating loss was $4.57 million, and net loss was $4.91 million.
- Cash flow: Operating activities used $6.46 million; investing activities used $1.68 million; financing activities provided $20.12 million. Cash and equivalents ended the year at $17.32 million, compared with $5.25 million a year earlier. The company described 2017 cash burn as approximately $6.6 million.
- Liquidity: Current assets were $20.74 million and current liabilities $7.85 million; working capital was $12.28 million. Management expected cash to fund operations into 2019, while stating additional capital would be needed.
- Debt: $10.0 million principal was outstanding under the Bridge Bank facility. The rate was 30-day U.S. dollar LIBOR plus 7.75% (9.12% at year-end); principal payments were scheduled to begin in February 2018, with maturity on July 1, 2020. The debt is secured by substantially all company assets other than intellectual property.
- Equity financing: The April 2017 offering raised approximately $10.3 million net. The company also received approximately $3.37 million net from at-the-market share sales during 2017 and another $3.57 million through March 7, 2018.
Material changes and business developments
- Product revenue growth reflected increased direct sales to new and repeat customers and higher distributor sales. Germany generated $7.99 million of product sales; all other countries together generated $5.39 million. No single customer, distributor, or grant agency exceeded 10% of 2017 total revenue.
- CytoSorb was commercially available in 45 countries through direct sales, distributors, or partners. Germany remained the principal product market. The company added Belgium and Luxembourg to its direct-sales activity and expanded Biocon’s exclusive distribution territory to Malaysia, extending that agreement through December 2022.
- The company expanded its Fresenius relationship, including minimum quarterly orders in specified territories through 2019 and a co-marketing program. It also entered a South African distribution partnership with Dr. Reddy’s in 2017.
- FDA approved the IDE for REFRESH 2, a planned pivotal U.S. cardiac-surgery trial of up to 400 patients measuring postoperative acute kidney injury. The company had begun screening at a site and anticipated at least two years to complete the study. U.S. approval was expected to require the PMA pathway.
- VetResQ launched in the U.S. veterinary market in January 2017. Other pipeline products—including HemoDefend, CytoSorb-XL, ContrastSorb, DrugSorb, and BetaSorb—remained in development and were not established sources of material commercial revenue.
Outlook, risks, and unusual items
- No specific financial guidance was provided. Management cited continued commercial expansion and clinical development, while expecting operating losses to continue for the foreseeable future.
- The independent auditor emphasized substantial doubt about the company’s ability to continue as a going concern. The company had accumulated losses of $152.31 million and said it would need additional capital for planned operations and clinical trials. The financial statements included no adjustments for the outcome of this uncertainty.
- Key execution risks include whether CytoSorb can demonstrate clinical benefit, complete REFRESH 2, obtain U.S. and other regulatory approvals, secure adequate reimbursement, expand adoption and maintain product margins. The European Sepsis Trial was not powered to establish mortality benefit; the REFRESH I study was not powered to measure clinical outcomes.
- Sales concentration in Germany, euro exchange-rate exposure, reliance on distributors and reimbursement systems, manufacturing scale-up, and potential dilution from future equity issuance are material risks. The company reported no current legal proceedings.
- FY 2017 included a $1.45 million foreign-currency transaction gain, compared with a $0.36 million loss in 2016, partly offset by $0.75 million net interest expense. The 2017 equity offering triggered repricing of certain warrants and a $335,731 dividend adjustment to income available to common stockholders. Stock-based compensation was $3.31 million.
- The company adopted ASU 2017-11 and restated comparative financial statements to change the accounting for warrants with down-round features. It also reported that new revenue-recognition rules adopted January 1, 2018 could defer some distributor and grant revenue.
Most important facts for investors to verify
- Cash runway assumptions and the timing, amount, and terms of any additional financing; monitor the auditor’s going-concern warning.
- Quarterly product-sales growth, repeat-order trends, geographic mix, and whether improved product margins persist.
- REFRESH 2 enrollment, timing, clinical results, and the regulatory steps required for U.S. commercialization.
- Actual reimbursement and adoption in Germany and other markets, plus distributor minimum-purchase performance and concentration risks.
- Debt amortization, interest expense, covenant compliance, potential equity dilution, and the effects of foreign-exchange movements.